Loading organizations...
§ Private Profile · Cascais, Lisboa, Portugal
Bio-decontamination solutions using patented solid hydrogen peroxide for healthcare, pharma, and biodefense sectors.
Based in Lisbon, Portugal, Delox develops advanced bio-decontamination systems utilizing a patented solid formulation of hydrogen peroxide, known as DeloxHP, to eliminate microorganisms in controlled environments. The company's core hardware technology, which includes the proprietary Delox AIR module, vaporizes this solid formulation to provide compact and scalable decontamination solutions for facilities operating across the healthcare, pharmaceutical, biodefense, and space sectors. To date, the enterprise has raised over €1.3 million in total capital to support its ongoing research, product refinement, and commercialization efforts. This financing includes a €750,000 seed funding round secured in May 2022, which was led by Kiilto Ventures with strategic participation from institutional investors Bionova Capital and Caixa Capital. Operating as a spin-off from the Faculty of Sciences at the University of Lisbon, Delox was founded in 2018 by João Silva, Fernando Antunes, and Fadhil Musa.
Delox has raised $19.0M across 1 funding round.
Delox has raised $19.0M in total across 1 funding round.
Delox has raised $19.0M in total across 1 funding round.
Delox's investors include Beta Capital, Caixa Capital, European Investment Bank.
Delox has raised $19.0M across 1 funding round. Most recently, it raised $19.0M Series A in February 2026.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Feb 13, 2026 | $19M Series A | Beta Capital | Caixa Capital Risc, European Investment Bank | Announced |